The European Union’s drug regulator is currently reviewing the risk of a body inflammation condition, which is directly connected to the Pfizer-BioNTech COVID-19 jab.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
According to the original report, published by the Epoch Times,
“The European Medicines Agency’s safety panel is looking into a report of a 17-year-old male teen from Denmark having developed Multisystem Inflammatory Syndrome (MIS). The teen has fully recovered, the agency said, adding the condition was reported after other COVID-19 vaccines.
“MIS is rare and its incidence rate before the COVID-19 pandemic estimated from five European countries was around 2 to 6 cases per 100,000 per year in children and adolescents below 20 years of age and below 2 cases per 100,000 per year in adults aged 20 years or more,” said the regulator in a statement. “At this stage, there is no change to the current EU recommendations for the use of COVID-19 vaccines.”
The condition was previously reported in people following a COVID-19 infection unrelated to vaccines, according to the health agency. But the Danish 17-year-old had no such medical history.
“It is important to understand that a careful assessment of MIS is ongoing, and it has not been concluded that mRNA COVID-19 vaccines cause MIS,” a Pfizer spokesperson told Reuters. The Epoch Times has contacted the company for comment.
Five cases of MIS were reported in the European Economic Area as of Aug. 19 after the Pfizer vaccine, while one case was reported with each Johnson & Johnson’s and Moderna’s vaccine, the European regulator said.
The European safety panel said it is investigating cases of blood clots in the veins, known as venous thromboembolism, in connection to the Johnson & Johnson shot.
“Venous thromboembolism was included in the risk management plan for COVID-19 Vaccine Janssen as a safety issue to be investigated, based on a higher proportion of cases of venous thromboembolism observed within the vaccinated group versus the placebo group in the first clinical studies used to authorize this vaccine,” according to the European Medicines Agency.”